CapsoVision Inc. Announces FDA Enforcement Discretion for At-Home Capsule Endoscopy Administration of CapsoCam Plus during COVID-19

CapsoVision Inc. Announces FDA Enforcement Discretion for At-Home Capsule Endoscopy Administration of CapsoCam Plus during COVID-19


Publication Title
PRNewswire
Publication/Creation Date
September 23 2020
Creators/Contributors
CapsoVision, Inc. (creator)
Food And Drug Administration (FDA) (contributor)
Media Type
Press Release
Persuasive Intent
Advertisement
Discursive Type
Inventions
Description
CapsoVision, an innovator in the gastroenterology diagnostics market, today announced that the U.S Food & Drug Administration (FDA) will apply enforcement discretion which allows at-home administration of the CapsoCam Plus small bowel capsule endoscope during the COVID-19 pandemic for patients who are determined eligible for at-home administration. The labeling addendum permits a fully remote capsule endoscopy procedure for eligible patients, eliminating the need for in-person interaction between clinic staff and patient.
HCI Platform
Ingestible
Relation to Body
In
Related Body Part
Digestive Tract
Marketing Keywords
CapsoVision, CapsoCam Plus
Source
https://www.prnewswire.com/news-releases/capsovision-inc-announces-fda-enforcement-discretion-for-at-home-capsule-endoscopy-administration-of-capsocam-plus-during-covid-19-301136268.html

Date archived
October 3 2021
Last edited
October 3 2021
How to cite this entry
CapsoVision, Inc.. (September 23 2020). "CapsoVision Inc. Announces FDA Enforcement Discretion for At-Home Capsule Endoscopy Administration of CapsoCam Plus during COVID-19". PRNewswire. Fabric of Digital Life. https://fabricofdigitallife.com/Detail/objects/5459